Clinical Data shows that Q-1802 has significant anti-tumor activity.

Duoning Biotechnology Group ("Duoning") announced a strategic partnership agreement with Branca Bunús Ltd. ("Branca Bunús"). Under this agreement, the two companies will collaborate on the development ...

During the quarter ended September 30, 2024, MacroGenics announced the achievement of $100.0 million in milestones from Incyte related to development progress of retifanlimab, following an agreement ...

Under the terms of the manufacturing supply agreement, FUJIFILM Diosynth Biotechnologies will provide secondary US-based ...

Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has appointed Thomas Guldager as vice ...

Single-use bioprocessing probes and sensors play a crucial role in the pharmaceutical and biopharmaceutical industries by providing real-time measurement of critical parameters, including pH, ...

In addition, the Company announces that, subject to TSXV approval, the Company has retained the services of Independent Trading Group (“ ITG ”) and Oak Hill Financial Inc. (“ Oak Hill ”) to provide ...

We are raising our fair value estimate for Waters to $340 per share, from $323 previously, based on cash flows generated since our last valuation update. Our valuation is based on discounted cash ...

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

Assiduous planning and flexibility were the factors critical to the project’s success. Focusing on these factors enabled us to move at a rapid pace, engage in parallel ramp-up efforts, and devise ...

As of early 2024, Thermo Fisher carried roughly $36 billion in long- and short-term obligations. The PPD acquisition materially increased its leverage (2.6 debt/EBITDA for 2023) but we anticipate this ...

The poster will be presented by Alan Ho, MD, PhD, Chief of the Head and Neck Oncology Service at Memorial Sloan Cancer Center (MSKCC), a clinical collaborator of HOOKIPA.